[go: up one dir, main page]

WO2004083241A3 - Btc-interacting proteins and use thereof - Google Patents

Btc-interacting proteins and use thereof Download PDF

Info

Publication number
WO2004083241A3
WO2004083241A3 PCT/JP2004/003699 JP2004003699W WO2004083241A3 WO 2004083241 A3 WO2004083241 A3 WO 2004083241A3 JP 2004003699 W JP2004003699 W JP 2004003699W WO 2004083241 A3 WO2004083241 A3 WO 2004083241A3
Authority
WO
WIPO (PCT)
Prior art keywords
btc
protein complexes
interacting proteins
disorders
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2004/003699
Other languages
French (fr)
Other versions
WO2004083241A2 (en
Inventor
Takeshi Sakamoto
Shizu Takeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of WO2004083241A2 publication Critical patent/WO2004083241A2/en
Publication of WO2004083241A3 publication Critical patent/WO2004083241A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Protein complexes are provided comprising BTC and one or more proteins selected from the group consisting of GROUP1. Methods of using the protein complexes in diagnosing diseases and disorders are also provided. In addition, the protein complexes are also useful in screen assays for identifying compounds effective in treating and/or preventing diseases and disorders associated with BTC and its interactors
PCT/JP2004/003699 2003-03-19 2004-03-18 Btc-interacting proteins and use thereof Ceased WO2004083241A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45600703P 2003-03-19 2003-03-19
US60/456,007 2003-03-19
US45994403P 2003-04-02 2003-04-02
US60/459,944 2003-04-02

Publications (2)

Publication Number Publication Date
WO2004083241A2 WO2004083241A2 (en) 2004-09-30
WO2004083241A3 true WO2004083241A3 (en) 2005-03-31

Family

ID=33032708

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/003699 Ceased WO2004083241A2 (en) 2003-03-19 2004-03-18 Btc-interacting proteins and use thereof

Country Status (1)

Country Link
WO (1) WO2004083241A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067764A2 (en) 2001-02-27 2002-09-06 Blanchette Rockefeller Neurosciences Institute Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US20090029873A1 (en) 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
JP2011529344A (en) 2008-07-28 2011-12-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート Stimulation-induced genomic profile markers for Alzheimer's disease
EP3586839A1 (en) 2008-07-28 2020-01-01 Blanchette Rockefeller Neurosciences, Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
CN102741693A (en) * 2009-10-02 2012-10-17 布朗歇特洛克菲勒神经科学研究所 Fibroblast growth patterns for diagnosis of alzheimer's disease
US9163032B2 (en) 2011-11-13 2015-10-20 Blanchette Rockefeller Neurosciences Insitute Esters of DCPLA and methods of treatment using the same
CA2880649C (en) 2012-08-01 2023-03-14 Elizabeth MCNALLY Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4)
FR3061179A1 (en) * 2016-12-22 2018-06-29 Universite Toulouse Iii-Paul Sabatier THERAPEUTIC PEPTIDES
PE20231093A1 (en) 2020-07-16 2023-07-18 Novartis Ag ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTISPECIFIC BINDING MOLECULES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARTEL P L ET AL: "ANALYZING PROTEIN-PROTEIN INTERACTIONS USING TWO-HYBRID SYSTEM", METHODS IN ENZYMOLOGY, ACADEMIC PRESS INC, SAN DIEGO, CA, US, vol. 254, 1995, pages 241 - 263, XP001013374, ISSN: 0076-6879 *
DATABASE EMBL [online] 1 June 2003 (2003-06-01), STRAUSBERG ET AL.: "Protein similar to prickle-like 1", XP002284782, Database accession no. Q80Y24 *
DUNBAR ANDREW J ET AL: "Structure-function and biological role of betacellulin", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, vol. 32, no. 8, August 2000 (2000-08-01), pages 805 - 815, XP002284781, ISSN: 1357-2725 *
KATOH MASUKO ET AL: "Identification and characterization of human PRICKLE1 and PRICKLE2 genes as well as mouse Prickle1 and Prickle2 genes homologous to Drosophila tissue polarity gene prickle.", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 11, no. 2, February 2003 (2003-02-01), pages 249 - 256, XP009032404, ISSN: 1107-3756 (ISSN print) *

Also Published As

Publication number Publication date
WO2004083241A2 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
AU2002366641A1 (en) Methods for inhibiting ocular processes
WO2004011611A3 (en) Taci antibodies and uses thereof
WO2003011115A3 (en) Peptide-based multimeric targeted contrast agents
WO2004074455A3 (en) Fc REGION VARIANTS
IN2014DN05011A (en)
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
CY1111863T1 (en) OPTIONS AGAINST DEATH RECEPTOR 4 (DR4) AND THEIR USES
EP2154157A3 (en) FC region variants
MXPA02012743A (en) Il-17 molecules and uses thereof.
WO2006038208A3 (en) Agents capable of downregulating an msf-a - dependent hif-1α and use thereof in cancer treatment
WO2004035742A3 (en) Sets of digital antibodies directed against short epitopes, and methods using same
AU2002364607A1 (en) Novel ligand involved in the transmigration of leukocytes .
WO2001072822A3 (en) Genes involved in intestinal inflammatory diseases and use thereof
WO2005042712A3 (en) Heterocyclic compounds and methods of making and using thereof
WO2004083241A3 (en) Btc-interacting proteins and use thereof
AU2003234198A1 (en) Novel genes, compositions, and methods for modulating the unfolded protein response
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
MXPA03000979A (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.
WO2004110365A3 (en) Liver related disease compositions and methods
WO2003076472A3 (en) Neoplasm specific antibodies and uses thereof
WO2002073212A3 (en) Diagnostic screens for alzheimer's disease
IL159479A (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis
WO2001074903A3 (en) Cd20/ige-receptor like molecules and uses thereof
WO2004005351A3 (en) Neoplasm specific antibodies and uses thereof
WO2003087051A3 (en) Methods for identifying allosteric sites

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase